KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Payables (2016 - 2026)

AbbVie has reported Payables over the past 14 years, most recently at $37.2 billion for Q4 2025.

  • Quarterly Payables rose 16.55% to $37.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $37.2 billion through Dec 2025, up 16.55% year-over-year, with the annual reading at $37.2 billion for FY2025, 16.55% up from the prior year.
  • Payables was $37.2 billion for Q4 2025 at AbbVie, roughly flat from $37.4 billion in the prior quarter.
  • Over five years, Payables peaked at $37.4 billion in Q3 2025 and troughed at $20.6 billion in Q1 2021.
  • The 5-year median for Payables is $28.2 billion (2023), against an average of $27.8 billion.
  • Year-over-year, Payables surged 62.12% in 2021 and then increased 2.81% in 2024.
  • A 5-year view of Payables shows it stood at $22.7 billion in 2021, then grew by 11.84% to $25.4 billion in 2022, then increased by 20.66% to $30.6 billion in 2023, then increased by 4.23% to $31.9 billion in 2024, then increased by 16.55% to $37.2 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Payables are $37.2 billion (Q4 2025), $37.4 billion (Q3 2025), and $34.2 billion (Q2 2025).